$IRON

Yu Jonathan Yen-Wen sold $1.3M of IRON

Yu Jonathan Yen-Wen (Chief Operating Officer) sold 18,612 shares of Disc Medicine, Inc. (IRON) at an average of $69.19 ($68.76–$69.92, $1.29M total) across 2 trades on 2026-06-16 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yu Jonathan Yen-Wen
Published Jun 18, 2026, 8:43 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 18, 2026, 8:45 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRON
Neutral
high confidence
Mentioned
$IRON
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRONNeutralLow
01

Why it matters

The disclosed event is an open-market sale by the COO totaling ~$1.29M, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor insider activity, but this specific disclosure is unlikely to drive a major repricing given the 10b5-1 structure and lack of new operating/financial information.

03

What to watch

The article provides no buy/sell context beyond this sale (e.g., total insider net activity, option exercises, or subsequent purchases), limiting inference.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed June 18; reflects June 16 sale activity.

Background

The article is an SEC Form 4 insider transaction disclosure for Disc Medicine, Inc. (IRON).

Company-level read

Ticker impact

$IRONNeutralHigh confidence
Context

Disc Medicine COO Yu Jonathan Yen-Wen sold about 18,612 shares in open-market transactions totaling ~$1.29M, per Form 4 filed June 18.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and small.

Evidence & confidence

The filing specifies an open-market sale and that the trades were under a pre-arranged Rule 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider sales can still be read by some traders as a mild caution signal about near-term outlook.

Key entities

  • IRON

    Disc Medicine, Inc.; subject of the Form 4 insider transaction disclosure.

  • Yu Jonathan Yen-Wen

    Chief Operating Officer who sold shares in open-market transactions under a 10b5-1 plan.

Related articles

$IRONMed

Disc Medicine, Inc. (IRON): Results of Operations and Financial Condition

Disc Medicine, Inc. (IRON) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 iron-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update • Completed Type A meeting with the FDA on bitopertin and aligned that the Phase 3 APOLLO study, if successful, can serve as the basis f

$NEEMed

SMALL-CAP MOVERS: Britain's bargain basement and the overseas buyers who can't believe their luck

The article reports AIM takeover activity: Gooch & Housego PLC is being acquired in a £346m deal, and Ramsdens Holdings PLC is set to be bought for £230m. It also notes NextEnergy Solar rose 10% after putting itself up for sale, and highlights large AIM share moves for Ironveld, Itaconix, Jersey Oil and Gas, Safestay, Galileo Resources, and Iofina. Iofina reported 393.3 tonnes H1 2026 and raised guidance to 460-485 tonnes.

$IRONMed

Ironveld shares jump 32% at 0.025p as processing plant hits sustained production

Ironveld PLC (AIM:IRON) shares rose 32% to 0.025p after the company said its dense media separation plant reached sustained production. It now runs 16 hours daily on double shift, processing 2.5-3.5 tonnes per hour and producing 1.4 tonnes/hour in-spec magnetite plus about 1 tonne/hour maghemite. Three clients secured, with a 5,000 tonnes/month buyer sampling; expansion options and Mintek study ongoing.

$IRONMed

Disc Medicine Presents Positive Clinical Updates at the 2026 European Hematology Association (EHA) Annual Meeting

Disc Medicine (NASDAQ:IRON) reported updated clinical data at the 2026 EHA meeting in Stockholm. In RALLY-MF, DISC-0974 showed durable overall anemia responses in myelofibrosis across subgroups, including 55% major hemoglobin response in non-transfusion dependent patients and transfusion independence in 64% (TD Low) and 50% (TD High). In HELIOS, bitopertin sustained PPIX reductions and improved light tolerance with favorable longer-term safety. A corporate call is set for June 15.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) shareholders, alleging materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.

$IRONLow

Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON

Rosen Law Firm said it is investigating potential securities claims for Disc Medicine, Inc. (NASDAQ: IRON) investors over allegations of materially misleading business information. The firm cited an FDA Complete Response Letter on Feb. 13, 2026 for Disc Medicine’s bitopertin NDA, citing uncertainties needing more evidence; IRON shares fell 22% that day.